These observations indicate that ErbB4 is cleaved in a subset of breast cancer tissues in vivo, and that mAbs targeted at ErbB4 may be a potential therapeutic option to suppress ErbB4 cleavage. The gene discussed is ERBB4; the disease is breast carcinoma.